ROCKVILLE, Md., Sept. 25, 2020 /PRNewswire/ -- REGENXBIO
Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company
seeking to improve lives through the curative potential of gene
therapy based on its proprietary NAV® Technology
Platform, today announced it will participate in the following
upcoming investor conferences, which will each be held in a virtual
meeting format:
SVB Leerink CybeRx Series: Rare Diseases & Genetic
Medicines
Date: Thursday,
October 1, 2020
Jefferies Virtual Gene Therapy/Editing
Summit
Date: Friday, October 2, 2020
Chardan Virtual 4th Annual Genetic Medicines
Conference
Date: Tuesday,
October 6, 2020
Fireside Chat: Tuesday, October 6,
2020 at 10:30 a.m. ET
A live webcast of the Chardan fireside chat can be accessed in
the Investors section of REGENXBIO's website
at www.regenxbio.com. An archived replay of the
fireside chat webcast will be available in the Investors section
of REGENXBIO's website for approximately 30 days
following the presentation.
About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company
seeking to improve lives through the curative potential of gene
therapy. REGENXBIO's NAV Technology Platform, a proprietary
adeno-associated virus (AAV) gene delivery platform, consists of
exclusive rights to more than 100 novel AAV vectors, including
AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV
Technology Platform Licensees are applying the NAV Technology
Platform in the development of a broad pipeline of candidates in
multiple therapeutic areas.
Contacts:
Tricia Truehart
Investor Relations and Corporate Communications
347-926-7709
Investors:
Eleanor Barisser, 212-600-1902
eleanor@argotpartners.com
Media:
David Rosen, 212-600-1902
david.rosen@argotpartners.com
View original
content:http://www.prnewswire.com/news-releases/regenxbio-to-participate-in-upcoming-investor-conferences-301138006.html
SOURCE REGENXBIO Inc.